All posts related to "psoriatic arthritis"

Reminder: Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Types of arthritis that make people more sensitive to sunlight

Lupus, psoriatic arthritis, and scleroderma are several types of arthritis that make people more sensitive to sunlight – either because of arthritis itself or the medications they take to treat it. It is important for these people to include sun protection as part of their self-management plan.

Stay sun safe image with beach essentialsThe sun radiates two types of “invisible” ultraviolet light that are harmful if you are exposed to it for a long period of time – ultraviolet A (UVA) can age the skin and ultraviolet B (UVB) can burn the skin. Both UVA and UVB can alter the DNA of skin cells, increasing the risk of skin cancer. For people living with lupus, psoriatic arthritis or scleroderma, sun exposure can make symptoms worse or increase damage to skin cells.

Sun sensitivity is a hallmark of lupus. People with lupus experience one or many of these symptoms:

  • “butterfly” rash over the bridge of the nose and the upper cheeks
  • scaly, purplish lesions on the face and neck
  • red, circular rashes on the chest, back and arms

Sun exposure can bring on these rashes or make existing rashes worse. Those with systemic lupus erythematosus find that exposure to the sun triggers a flare, including joint pain, fatigue, and fever.

Continue reading

Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Complete this short “Co-Morbidity Survey” to stand-up to spondyloarthritis!

Please take a few minutes to complete a short survey to help the Canadian Spondylitis Association help you. 

Picture of a spine for the co-morbidity spondyloarthritis surveyA co-morbidity is not a side effect.

A focus of the Canadian Spondylitis Association (CSA) in 2018 will be on highlighting and educating members about co-morbidities that are associated with spondyloarthritis. The CSA are forming partnerships to bring you the education and support that you should have. Individuals are sometimes diagnosed because of a co-morbidity or by a professional outside of rheumatology. In some cases, diagnosis is delayed due to the complexities of spondyloarthritis and its many co-morbidities.

Stand-up to spondyloarthritis! Together we can make a difference. Please take a few minutes of your time to complete a short survey to help the CSA help you.

The CSA will be updating their website with information on co-morbidities and include articles in upcoming newsletters highlighting a co-morbidity.

Complétez ce court sondage pour tenir tête à la spondylarthrite!

S’il vous plaît, prenez quelques minutes afin de complétez ce court sondage pour aider l’Association Canadienne de Spondylarthrite à vous aider! 

Picture of a spine for the co-morbidity spondyloarthritis surveyUne co-morbidité n’est pas un effet secondaire.

En 2018, l’ACS mettra l’accent sur la sensibilisation et l’éducation des membres sur les co-morbidités associées à la spondylarthrite. Nous formons des partenariats pour vous apporter l’éducation et le soutien dont vous avez besoin. Les individus sont parfois diagnostiqués à cause d’une co-morbidité ou par un professionnel de la santé autre que la rhumatologie. Dans certains cas, le diagnostic est retardé en raison de la complexité de la spondylarthrite et de ses nombreuses co-morbidités.

Tenez tête à la spondylarthrite! Ensemble nous pouvons faire la différence. Veuillez prendre quelques minutes de votre temps pour remplir un court sondagepour nous aider – à vous aider.

Nous mettrons à jour notre site Web avec des informations sur les co-morbidités et incluant des articles, dans les prochains bulletins d’informations mettant en évidence une co-morbidité.

Interviews from the 2018 #CRArthritis Facebook and Twitter Live event are now available on Facebook and YouTube!

Thanks to our fans and followers, Arthritis Broadcast Network’s 2018 #CRArthritis Facebook and Twitter Live event reached over 94,205 people to date! 

We did it! The Arthritis Broadcast Network (ABN) #CRArthritis Facebook and Twitter Live event at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting and Arthritis Health Professions Association (AHPA) Annual Meeting conducted a total of 39 interviews (7 more than last year) in a little over 48 hours. Thank you to all of our interviewers, interviewees, and online audience who participated in the event. Because of you, the #CRArthritis event have informed and educated over 94,205 people to date. We’d say that’s an unqualified success, and you were a central part of making it happen – thank you!

CRArthritis

Continue reading

Call for patient input on ixekizumab (Taltz) for the treatment of psoriatic arthritis

Stickman with megaphone calling for patient inputDo you have psoriatic arthritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for ixekizumab (Taltz) for the treatment of psoriatic arthritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

You’re invited! Free 2017 Calgary Ankylosing Spondylitis & Psoriatic Arthritis Public Information Forum

AS and PsA Forum BannerJoin guest speakers for a free information session to learn more about ankylosing spondylitis and psoriatic arthritis and how to effectively manage these conditions.

Date: Saturday, November 18, 2017
Time: 8:30 am-12:30 pm
Speaker presentations start at 9:00 am

Location:
WINSPORT Multi-purpose Room
88 Canada Olympic Road SW
Calgary, Alberta, T3B 5R5

To register online, please click here or email execdirector@spondylitis.ca or phone (705) 715-2162. On-site registration opens at 8:30 am. Refreshments will be served.

The following topics will be discussed:
Disease overview & diagnosis
Treatment options
What’s new and on the horizon
Pain management
Non-pharmacologic treatment

Guest speakers:
Dr. Diane Mosher (Rheumatologist)
Dr. Olga Zouzina (Rheumatologist)
Carolyn Johns (Physiotherapist)
Alex Charlton (pharmacist)
Patient Speaker

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis?

Stickman with megaphone calling for patient inputCall for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input

Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on guselkumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for guselkumab for the treatment of moderate to severe plaque psoriasis.

Guselkumab belongs to the biologic response modifier class of inflammatory arthritis medications. It works by blocking the interleukin (IL)-23 molecule, a cytokine that plays a key role in plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about public reimbursement of medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading